186 related articles for article (PubMed ID: 33683075)
1. Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications.
Wu J; Cotliar R
J Drugs Dermatol; 2021 Mar; 20(3):290-294. PubMed ID: 33683075
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.
Minder EI; Barman-Aksoezen J; Schneider-Yin X
Clin Pharmacokinet; 2017 Aug; 56(8):815-823. PubMed ID: 28063031
[TBL] [Abstract][Full Text] [Related]
3. [Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide].
de Baat C; Phoa KH; Zweers PGMA; Bolling MC; Rozema FR; Vissink A
Ned Tijdschr Tandheelkd; 2020 Apr; 127(4):237-243. PubMed ID: 32459219
[TBL] [Abstract][Full Text] [Related]
4. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.
Wensink D; Wagenmakers MAEM; Langendonk JG
Expert Rev Clin Pharmacol; 2021 Feb; 14(2):151-160. PubMed ID: 33507118
[No Abstract] [Full Text] [Related]
5. A review and update on melanocyte stimulating hormone therapy: afamelanotide.
Fabrikant J; Touloei K; Brown SM
J Drugs Dermatol; 2013 Jul; 12(7):775-9. PubMed ID: 23884489
[TBL] [Abstract][Full Text] [Related]
6. Afamelanotide: A Review in Erythropoietic Protoporphyria.
Kim ES; Garnock-Jones KP
Am J Clin Dermatol; 2016 Apr; 17(2):179-85. PubMed ID: 26979527
[TBL] [Abstract][Full Text] [Related]
7. Pseudoleucoderma after injections of afamelanotide in a patient with atopic dermatitis.
von Bartenwerffer W; Siebenhaar G; Hunzelmann N
Acta Derm Venereol; 2011 Sep; 91(5):578-9. PubMed ID: 21597671
[No Abstract] [Full Text] [Related]
8. Afamelanotide in the Treatment of Dermatologic Disease.
McNeil MM; Nahhas AF; Braunberger TL; Hamzavi IH
Skin Therapy Lett; 2018 Nov; 23(6):6-10. PubMed ID: 30517779
[TBL] [Abstract][Full Text] [Related]
9. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.
Biolcati G; Marchesini E; Sorge F; Barbieri L; Schneider-Yin X; Minder EI
Br J Dermatol; 2015 Jun; 172(6):1601-1612. PubMed ID: 25494545
[TBL] [Abstract][Full Text] [Related]
10. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria.
Minder EI; Schneider-Yin X
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):43-53. PubMed ID: 25470471
[TBL] [Abstract][Full Text] [Related]
11. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice.
Wensink D; Wagenmakers MAEM; Barman-Aksözen J; Friesema ECH; Wilson JHP; van Rosmalen J; Langendonk JG
JAMA Dermatol; 2020 May; 156(5):570-575. PubMed ID: 32186677
[TBL] [Abstract][Full Text] [Related]
12. Afamelanotide for Erythropoietic Protoporphyria.
Langendonk JG; Balwani M; Anderson KE; Bonkovsky HL; Anstey AV; Bissell DM; Bloomer J; Edwards C; Neumann NJ; Parker C; Phillips JD; Lim HW; Hamzavi I; Deybach JC; Kauppinen R; Rhodes LE; Frank J; Murphy GM; Karstens FPJ; Sijbrands EJG; de Rooij FWM; Lebwohl M; Naik H; Goding CR; Wilson JHP; Desnick RJ
N Engl J Med; 2015 Jul; 373(1):48-59. PubMed ID: 26132941
[TBL] [Abstract][Full Text] [Related]
13. A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria.
Spichty R; Balimann M; Barman J; Minder EI
J Pharm Biomed Anal; 2013 Mar; 75():192-8. PubMed ID: 23277150
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies.
Lengweiler S; Kreim S; Barman-Aksözen J; Maurer M; Minder EI
Skin Pharmacol Physiol; 2015; 28(2):103-13. PubMed ID: 25402764
[TBL] [Abstract][Full Text] [Related]
15. Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.
Minder EI
Expert Opin Investig Drugs; 2010 Dec; 19(12):1591-602. PubMed ID: 21073357
[TBL] [Abstract][Full Text] [Related]
16. Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States.
Resnik SR; Targett D; Resnik BI
J Drugs Dermatol; 2023 Sep; 22(9):941-949. PubMed ID: 37683058
[TBL] [Abstract][Full Text] [Related]
17. Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study.
Minder AE; Barman-Aksoezen J; Schmid M; Minder EI; Zulewski H; Minder CE; Schneider-Yin X
Ther Adv Rare Dis; 2021; 2():26330040211065453. PubMed ID: 37181106
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo.
Grimes PE; Hamzavi I; Lebwohl M; Ortonne JP; Lim HW
JAMA Dermatol; 2013 Jan; 149(1):68-73. PubMed ID: 23407924
[TBL] [Abstract][Full Text] [Related]
19. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.
Harms JH; Lautenschlager S; Minder CE; Minder EI
Photochem Photobiol; 2009; 85(6):1434-9. PubMed ID: 19656325
[TBL] [Abstract][Full Text] [Related]
20. Alpha-melanocyte stimulating hormone analogues: the perils and the promise.
Mazza JM; Zippin JH
J Drugs Dermatol; 2009 Aug; 8(8):772-6. PubMed ID: 19663117
[No Abstract] [Full Text] [Related]
[Next] [New Search]
